Trade Gilead Sciences Inc - GILD CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.27 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 88.72 |
| Open | 88.13 |
| 1-Year Change | 16.14% |
| Day's Range | 87.81 - 89.81 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 21, 2024 | 87.95 | -0.18 | -0.20% | 88.13 | 88.13 | 87.95 |
| Nov 20, 2024 | 88.60 | 0.85 | 0.97% | 87.75 | 89.03 | 86.92 |
| Nov 19, 2024 | 87.75 | -0.45 | -0.51% | 88.20 | 88.53 | 86.02 |
| Nov 18, 2024 | 88.36 | 1.21 | 1.39% | 87.15 | 88.90 | 86.40 |
| Nov 15, 2024 | 88.41 | -3.39 | -3.69% | 91.80 | 92.11 | 88.16 |
| Nov 14, 2024 | 91.80 | -0.82 | -0.89% | 92.62 | 93.32 | 90.59 |
| Nov 13, 2024 | 92.62 | -1.49 | -1.58% | 94.11 | 94.28 | 91.58 |
| Nov 12, 2024 | 94.11 | -2.69 | -2.78% | 96.80 | 97.94 | 94.05 |
| Nov 11, 2024 | 96.80 | 0.53 | 0.55% | 96.27 | 98.80 | 95.47 |
| Nov 8, 2024 | 96.51 | -0.44 | -0.45% | 96.95 | 97.59 | 94.86 |
| Nov 7, 2024 | 97.20 | 3.05 | 3.24% | 94.15 | 98.22 | 92.83 |
| Nov 6, 2024 | 94.15 | 4.43 | 4.94% | 89.72 | 96.65 | 89.70 |
| Nov 5, 2024 | 89.72 | 0.44 | 0.49% | 89.28 | 91.38 | 87.95 |
| Nov 4, 2024 | 89.38 | 0.67 | 0.76% | 88.71 | 90.65 | 88.55 |
| Nov 1, 2024 | 89.11 | 1.72 | 1.97% | 87.39 | 89.51 | 86.95 |
| Oct 31, 2024 | 87.95 | 1.20 | 1.38% | 86.75 | 89.23 | 86.51 |
| Oct 30, 2024 | 88.26 | 1.07 | 1.23% | 87.19 | 88.50 | 86.55 |
| Oct 29, 2024 | 87.50 | -0.85 | -0.96% | 88.35 | 88.72 | 86.76 |
| Oct 28, 2024 | 88.55 | -0.23 | -0.26% | 88.78 | 89.31 | 88.38 |
| Oct 25, 2024 | 88.56 | 0.41 | 0.47% | 88.15 | 89.66 | 88.15 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Gilead Company profile
What is Gilead Sciences?
What does the company do?
A research-based biopharmaceutical company, Gilead Sciences, discovers, produces and markets innovative healthcare products that are capable of transforming and simplifying medical care for people, who suffer from life-threatening diseases globally.
A bit of Gilead Sciences’ history
Gilead Sciences was established in June 1987. The company primarily focused on antiviral medicines. It concentrated on gene therapy, estimating the potential of genetic code blockers. The development and research of small molecule antiviral therapeutics started in 1991 with licensing of a group of nucleotide compounds (tenofovir was one of them) that further became widely-used anti-retroviral medicines. In 1990, Gilead collaborated with Glaxo for the development and research of genetic code blockers, known as antisense.
Who founded Gilead Sciences?
Gilead Sciences was founded by Michael L. Riordan, a 29-year-old doctor, who graduated from the Johns Hopkins School of Medicine, Washington University of St. Louis and the Harvard Business School. Riordan worked as the company’s CEO from its inception till 1996.
Current size, team and locations
Headquartered in Foster City, California, US, the company operates across 6 continents and has a team of almost 9,000 employees. Gilead has a portfolio of 24 marketed products and is rapidly expanding. The research and development division works on over 400 clinical studies, evaluating compounds that potentially will become the next generation of efficient medicines.
Quick facts about Gilead Sciences
- Developing access programmes to provide HIV and viral hepatitis medicines at significantly reduced prices in 134 low- and middle-income countries, the company serves approximately 10 million people in the developing world with Gilead’s HIV/AIDS therapies.
- It is said that Riordan wanted to attract Warren Buffett as Gilead’s board member and investor, but was unsuccessful.
- In 2005 the company created the Gilead Foundation, a non-profit organisation that is trying to improve the well-being and health of underserved communities in the United States and globally.
- In 2016 the company gained $30.4 billion in revenue and was ranked the second in the Barron’s 500 rankings. The company also became the first in Business Insider’s list of top companies to work for.
How to learn the Gilead Sciences share price?
Gilead Sciences shares are listed and traded on the NASDAQ stock exchange under the ticker symbol GILD. The company is a component of the US Tech 100, S&P 500 and S&P 100 indices. Join Capital.com to trade CFDs on the Gilead Sciences share price fluctuations and follow the GILD chart in real-time.
| Industry: | Pharmaceuticals (NEC) |
333 Lakeside Dr
FOSTER CITY
CALIFORNIA 94404-1147
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com